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AIgA Nephropathy: The Presence of Familial Disease Does Not Confer
an Increased Risk for Progression
Claudia Izzi, MD, Pietro Ravani, MD, Diletta Torres, MD, Elisabetta Prati, MD,
Battista Fabio Viola, MD, Simona Guerini, MD, Marina Foramitti, MD, Giovanni Frascà, MD,
Antonio Amoroso, MD, Gian Marco Ghiggeri, MD, Francesco Paolo Schena, MD,
and Francesco Scolari, MD
Background: Immunoglobulin A (IgA) nephropathy is the most common form of glomerulonephritis worldwide.
amilial and sporadic cases are recognized, and a locus associated with the familial form of the disease was
apped to chromosome 6. Recent data suggest the familial IgA nephropathy form may have a poorer outcome than
he sporadic form. Methods: We tested the hypothesis of unequal survival rates between the 2 forms of disease by
nalyzing time from biopsy to end-stage renal disease in patients of Italian ancestry; 589 patients with sporadic and
6 patients with familial IgA nephropathy. Results: Overall 10- and 20-year renal survival probabilities of the cohort
s a whole were 71% and 50%, respectively. Macroscopic hematuria was the modality of clinical presentation in 51%
f patients with familial IgA nephropathy and 39% of patients with sporadic IgA nephropathy. At univariable
nalysis, the sporadic form of IgA nephropathy was associated significantly with increased risk for renal death.
owever, patients with the sporadic form tended to be more hypertensive and diagnosed later, with signs of more
dvanced renal disease than those with familial disease at baseline. In the regression model, form of disease lost
ny independent effect. Only male sex, lower baseline glomerular filtration rate, greater proteinuria, and histopatho-
ogic score proved to be independent predictors of disease progression. Treatment with steroids or angiotensin-
onverting enzyme inhibitors was associated with improved outcomes. Conclusion: Our study does not confirm
hat familial IgA nephropathy has a worse prognosis than the sporadic form. The similar renal phenotype may
upport a common pathogenic mechanism underlying familial and sporadic IgA nephropathy. Am J Kidney Dis
7:761-769.
2006 by the National Kidney Foundation, Inc.
NDEX WORDS: Familial immunoglobulin A (IgA) nephropathy; glomerular filtration rate; renal survival; risk factors;
poradic immunoglobulin A (IgA) nephropathy.
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tMMUNOGLOBULIN A (IgA) nephropathy
is a relatively newly recognized disease, first
escribed by Berger and Hinglais1 in 1968. After
heir seminal article, the disorder soon was recog-
ized as the most common primary glomerulone-
hritis in the world, comprising 25% to 50% of
enal biopsy diagnoses.2,3 Once considered a
elatively benign condition, longitudinal fol-
ow-up studies showed that 40% of patients
rogressed to end-stage renal disease by 15 years
fter the time of renal biopsy.4 In the last 20
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atients reported clinical, laboratory, and patho-
ogical characteristics that predict progressive
enal disease.5-12 Impaired renal function at the
ime of renal biopsy, high glomerular histopatho-
ogic scores, proteinuria with protein greater
han 1 g/24 h, and hypertension have emerged as
trong predictors of poor renal survival.
Despite considerable research, the pathogene-
is of IgA nephropathy is poorly understood, and
he true mechanism of mesangial IgA targeting
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IZZI ET AL762emains hypothetical.13 However, observations
ave accumulated indicating that genetic factors
ay be important in disease susceptibility.14 Re-
ently, the role of genetic factors in the develop-
ent of IgA nephropathy was definitely estab-
ished, and a chromosomal position of the trait
as identified on 6q22-23.15 Traditionally, the
trongest evidence of a role of genetic predispo-
ition in the development of IgA nephropathy
as provided by descriptive reports of familial
ggregation of the disorder that appears to be
ery common. To date, more than 100 families
ith multiple members with IgA nephropathy
ave been reported from several ethnic back-
rounds.16,17 Moreover, in some series, familial
orms of the disease may represent up to 15% to
0% of cases of primary disease.18
To date, only 2 studies examined the renal
henotype of patients with familial IgA nephrop-
thy. According to Julian et al,19 familial and
onfamilial IgA nephropathy cannot be differen-
iated by clinical features of the disease. How-
ver, more recently, Schena et al20 reported that
atients with familial IgA nephropathy had a
oorer outcome than those with sporadic IgA
ephropathy. However, none of those studies
as powerful enough to provide a reliable esti-
ate of any association with disease progression
hile considering potential confounders.
The purpose of the present work, including a
arge cohort of adults with biopsy-proven IgA
ephropathy, is to compare the renal phenotype
f patients with sporadic and familial IgA ne-
hropathy, accounting for baseline clinical char-
cteristics and other risk factors known to impact
n renal outcome.
METHODS
gA Nephropathy Patient Population
This historical cohort study includes 685 Italian patients
ith IgA nephropathy recruited by the European IgA Ne-
hropathy Consortium: 589 patients had sporadic disease
nd 96 patients had familial IgA nephropathy. Patients with
amilial IgA nephropathy belonged to 40 families; 34 were
uclear families, including 2 or more first-degree affected
embers; and 6 were extended families, including, in addi-
ion to at least 2 first-degree affected members, other more
istant affected relatives. Demographic, clinical, and patho-
ogical data from adults with biopsy-proven IgA nephropa-
hy were collected from databases in Brescia and Bari, the 2
talian coordinating centers of the European IgA Consor-
ium, a collaborative study group including nephrologists
nd geneticists from Italy, Germany, and Greece. Data were collected retrospectively from university hospitals and asso-
iated tertiary-care centers by using biopsy registries, clini-
al inpatient and outpatient records, and discharge summa-
ies at each institution. The study was approved by the local
thical review committees. All individuals participating in
he study gave informed consent according to the Helsinki
eclaration.
iagnostic Criteria and Definitions
Biopsy-proven IgA nephropathy was based on the pre-
ominance of IgA deposits in the mesangial area of glo-
eruli in patients with recurrent macroscopic hematuria or
ersistent microscopic hematuria and/or proteinuria. Individu-
ls with secondary forms of IgA nephropathy were excluded
rom the study. A detailed family history was obtained from
ll patients with IgA nephropathy. Moreover, all first-degree
amily members of patients with IgA nephropathy under-
ent urinalysis. Sporadic IgA nephropathy was diagnosed
hen the presence of the disease occurred only in the patient
nd family members had negative results at urinalysis.
amilial IgA nephropathy was diagnosed when at least 2
rst-degree family members had biopsy-proven IgA ne-
hropathy.
aseline Clinical, Laboratory, and
istopathologic Data
At the time of renal biopsy (baseline data), the following
emographic and clinical data were collected: age, sex,
lood pressure, urinary protein excretion (grams per 24
ours), serum creatinine (milligrams per deciliter [SI, micro-
oles per liter]), and glomerular filtration rate (GFR; millili-
ers per minute [SI, milliliters per second]). Treatment with
n angiotensin-converting enzyme (ACE) inhibitor and/or
ngiotensin II receptor blocker (ARB) and immunosuppres-
ive therapy with steroids also were considered. Proteinuria
as categorized as mild for protein less than 1 g/24 h,
oderate at 1 to 3 g/24 h, and severe at greater than 3 g/24 h.
FR was estimated based on the 4-variable Modification of
iet in Renal Disease (MDRD) formula.21 Categories of
enal function deterioration are defined based on the Na-
ional Kidney Foundation–Dialysis Outcomes Quality Initia-
ive classification as absent/mild at greater than 60 mL/min
1.00 mL/s), moderate at 60 to 30 mL/min (1.00 to 0.50
L/s), and severe/advanced at less than 30 mL/min (0.5001
L/s).22 Hypertension is defined as systolic blood pressure
f 130 mm Hg or greater and/or diastolic blood pressure of
0 mm Hg or greater; patients are defined as having arterial
ypertension if they had a history of hypertension requiring
reatment or developed hypertension at the time of diagno-
is. The existence or absence of at least 1 documented
pisode of macroscopic hematuria was investigated. His-
opathologic renal lesions were graded according to the
orld Health Organization classification.23 Three grades
G) were identified: (1) G1 (mild disease): normal renal
arenchyma or evidence of mild mesangial cell proliferation
r mesangial matrix expansion (minimal lesions); (2) G2
moderate disease): focal and segmental glomerular sclero-
is with the presence of floccular adhesions to Bowman
apsule, low number of extracapillary proliferations (cres-
ents), and mild interstitial infiltrates (focal and segmental
l
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FAMILIAL AND SPORADIC IGA NEPHROPATHY 763esions); and (3) G3 (severe disease): severe involvement of
lomeruli (partial or total glomerular sclerosis), tubules
tubular atrophy and thickness of basement membranes),
nterstitium (numerous infiltrates and severe interstitial fibro-
is), and vessels (intimal thickening and arteriolar thicken-
ng with lumen reduction).
ollow-Up and Outcome
During follow-up, clinical and laboratory data for patients
ith familial and sporadic IgA nephropathy were obtained at
ifferent times, with frequency depending on the severity of
enal disease. Patients were followed up after diagnosis until
hey died or reached end-stage renal disease (ESRD). To
void loss to follow-up, patients were contacted by tele-
hone between September 1 and December 31, 2004
study end date), if they were not known to already be on
ialysis therapy or dead. Two outcome measures were
onsidered at the end of follow-up: (1) the composite end
oint of halving the GFR value or ESRD (dialysis or renal
ransplantation), and (2) reaching ESRD only. Death and
oss to follow-up were considered in sensitivity analysis (see
tatistical analysis).
tatistical Analysis
Study power and sample size. Previous reports de-
cribed a median time to ESRD of 25 to 30 years in patients
ith the sporadic forms of IgA nephropathy5,11 and risk for
rogression up to 100% greater in those with familial forms
f the disease.20 On this basis, we expected that the Italian
opulation of the European consortium (700 subjects with
6:1 ratio of sporadic to familial form) would permit
etection of a relative risk for event occurrence of 0.6 or less
r 1.7 or greater with a power of 0.9 and a type I error
robability of 0.05.
Survival functions. Times from diagnosis (biopsy date)
o event (halving the GFR or renal replacement therapy start
ates) or censoring (last scheduled visit date, death, or loss
o follow-up) were described by using the Kaplan-Meier
ethod. Univariable comparisons were conducted by using
og-rank test. The Cox proportional hazards procedure was
sed to model time to event as a function of the form of IgA
ephropathy (sporadic versus familial). Potential correlation
ithin family members was accounted for by correcting the
obust variance–covariance matrix of the estimators with the
atrix of the independent groups’ (clusters) efficient score
esiduals.24 Covariates considered to develop the survival
odel included all risk factors previously described unless
iolation of the hazard proportionality was present. Stratifi-
ation was used to build the final regression model and
heck its consistency. Furthermore, the largest possible
eaningful model initially considered included clinically
onsistent and interpretable interaction terms, following the
ule of 10 (1 parameter/10 events) and considering the
verall model fit and hazard proportionality. The final model
as stratified by referral coordinating centers (Brescia and
ari) and age tertiles because they did not satisfy the
roportionality assumption and age was included in the
DRD formula. Strata were obtained by factoring these 2
ariables into the 6 possible combinations. Proteinuria and
aseline renal function were tested as both continuous and sategorical variables. A maximum-likelihood procedure was
sed to estimate regression coefficients, and contribution of
he covariates to explain the dependent variable was as-
essed by means of a 2-tailed Wald test, with P less than 0.05
onsidered significant. The –2 log likelihood ratio statistic
as used for goodness-of-fit comparison. Model specifica-
ion and overall fit were checked by reestimation; formal
ests based on Schoenfeld, martingale, and Cox-Snell residu-
ls; and testing the interaction with time of variables in the
odel. Influence analysis was conducted based on efficient
core residuals. Sensitivity analysis was conducted consider-
ng the length of observation time and reasons for loss to
ollow-up. All analyses were performed using STATA 9 SE
StataCorp, College Station, TX).
RESULTS
atient Characteristics
Table 1 lists demographic and baseline charac-
eristics of the study cohort as a whole and by
atients with the familial versus sporadic IgA ne-
hropathy forms. The study population at the time
f renal biopsy had an average age of 34.8 14.8
SD) years; 75.4% of patients were men, 40.6%
ere hypertensive, and 41.1% had macroscopic
ematuria at onset. Baseline GFR was 78.5 41.1
L/min (1.30 mL/s); serum creatinine, 1.47 
.13 mg/dL (130 mol/L); and proteinuria, 1.24
.31 g/24 h or protein. At the time of renal biopsy,
requency of arterial hypertension, severity of
istological lesions, serum creatinine levels, and
roteinuria were significantly greater (Table 1) in
atients with sporadic IgA nephropathy com-
ared with those with familial disease. Of note,
acroscopic hematuria was the modality of clini-
al presenting feature in 51% of patients with
amilial IgA nephropathy and 39.2% of patients
ith sporadic disease (P 0.010).
enal Outcome
After a mean follow-up of 77 months (median,
5 months; range, 3 to 378 months), 177 patients
eached the combined end point of halving GFR
r ESRD (4,423 patient-years at risk; incidence
ate, 3.4/100 patient-years). By univariate analy-
is, in the entire population, renal survival prob-
bilities were 0.67 (95% confidence interval [CI],
.62 to 0.72) at 10 years and 0.38 (95% CI, 0.29
o 0.46) at 20 years. Of those censored, 9 patients
ied and 11 patients were lost to follow-up.
vent occurrence was appreciably greater among
atients with sporadic forms (4.4 versus 2.3/100
erson-years). Considering ESRD only and cen-
oring patients with halving of GFR, events
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IZZI ET AL764ccurred in 143 patients. With this outcome
easure, renal survival probabilities were 0.71
95% CI, 0.66 to 0.76) at 10 years and 0.50 (95%
I, 0.41 to 0.58) at 20 years. As expected, older
ge, male sex, presence of hypertension (Fig
C), onset type with microhematuria (Fig 1B),
igher histological grade (Fig 1A), lower GFR,
nd greater proteinuria were associated with sig-
ificantly worse survival. As far as the main
xposure of interest was concerned, patients with
he familial form showed crude survival probabili-
ies (combined end point of halving GFR or
SRD) of 0.77 and 0.63 at 10 and 20 years
ersus 0.64 and 0.28 for the sporadic forms
P 0.003; Fig 1D), respectively. To obtain an
nbiased estimate of the exposure–outcome
elationship of interest, the mentioned confound-
ng factors were controlled with multivariable
nalysis. In the Cox model, male sex, severity of
istological lesions, baseline GFR, and protein-
ria level were all strong and independent predic-
ors of disease progression. Patients adminis-
ered converting-enzyme inhibitors and those
Table 1. Characteristics of the Cohort as a Whole a
Variable All (N 685)
ge (y) 34.8 14.8
ale sex 517 (75.4)
ypertension 306 (40.6)
acrohematuria 282 (41.1)
erum creatinine (mg/dL) 1.47 1.13
FR (MDRD4; mL/min) 78.5  41.1
roteinuria (g/L) 1.24 1.31
hronic kidney disease
Absent-mild 467 (68.1)
Moderate 140 (20.4)
Severe-advanced 78 (11.3)
roteinuria (g/L)
1 353 (51.5)
1-3 253 (36.9)
3 79 (11.5)
istological grade
1 231 (33.7)
2 266 (38.8)
3 188 (27.4)
teroid and ACE-inhibitor/ARB use 108 (15.7)
ACE inhibitor/ARB only 211 (30.8)
Steroid only 32 (4.6)
Neither drug 334 (48.7)
NOTE. Qualitative variables expressed as absolute freq
ean SD. Chi-square and t-tests were used for comparis
erum creatinine in mg/dL to mol/L, multiply by 88.4; GFRreated with steroids had a significantly de- treased risk for event occurrence. Conversely,
he association of the sporadic form with renal
ailure was no longer present (Fig 2; Table 2). No
ignificant second-order interaction was found
etween any combination of these variables.
esults were the same when the outcome was
SRD only (and patients halving GFR were
ensored), excluding patients with follow-up
horter than 1 year (n  71) or censoring those
ith follow-up longer than 25 years (n 14), as
ell as assuming that the 20 subjects lost to
ollow-up before the study end date had devel-
ped the event of interest.
DISCUSSION
This study describes the long-term outcome of
ne of the largest cohorts of patients with IgA
ephropathy reported to date. Considering the
ntire population (familial and sporadic cases)
nd ESRD as outcome measure, overall 10- and
0-year renal survival rates were 71% and 50%,
espectively. This is similar to previous reports.
ctuarial renal survival at 10 years reported by
Type of IgA Nephropathy at Time of Renal Biopsy
Sporadic (n 589) Familial (n 96) P
35.28 14 32.23  14 0.064
451 (76.5) 66 (68.7) 0.099
278 (47.2) 28 (29.1) 0.001
231 (39.2) 51 (53.1) 0.010
1.51  1.18 1.24  0.71 0.002
77.0  39.4 87.7  49.7 0.047
1.27  1.28 1.12 1.5 0.370
395 (67) 72 (75)
121 (20.5) 19 (19.7) 0.104
73 (12.3) 5 (5.2)
291 (49.4) 62 (64.5)
227 (38.5) 26 (27) 0.002
71 (12) 8 (8.33)
184 (31.2) 47 (48.9)
239 (40.5) 27 (28.1) 0.003
166 (28.1) 22 (22.9)
101 (17.1) 7 (7.29)
0.015185 (31.4) 26 (27)24 (4) 8 (8.3)
279 (47.3) 55 (57.2)
and percentage, and quantitative variables expressed as
esults that have P0.05 are indicated in bold. To convert
min to mL/s, multiply by 0.01667.nd by
uency
ons. Rhe majority of studies performed in Europe,
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FAMILIAL AND SPORADIC IGA NEPHROPATHY 765sia, and the United States during the last 2
ecades is highly variable, ranging from 57% to
4%.5-12 This variability in long-term outcome
f patients with IgA nephropathy may reflect
ifferences in genetic influences, frequency of
rinary screening, and criteria for renal biopsy. A
eview of patients from 3 continents suggests
Fig 1. Kaplan-Meier renal
urvival functions by (A) histo-
ogical grade, (B) macrohema-
uria versus microhematuria,
C) presence of hypertension,
nd (D) sporadic versus famil-
al IgA nephropathy from the
enal biopsy, with halving of
aseline estimated GFR and
SRD as the combined end
oint.hat a lead-time bias in establishing the diagnosis
ontributes to the variation in long-term out-
omes by different centers.25
In our study, the size of the entire cohort and
ength of follow-up allowed meaningful compari-
on of factors that affected long-term outcome.
y using univariate analysis, multiple risk fac-
Fig 2. Stratified Cox
model of time to halving of
baseline estimated GFR and
ESRD (see Table 2 for de-
tails). Log-scale plot of haz-
ard ratios (HRs) and 95% CIs
for disease progression. To
convert GFR in mL/min to
mL/s, multiply by 0.01667.
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IZZI ET AL766ors were associated significantly with poorer
utcome. They included older age, male sex,
rterial hypertension, absence of history of macro-
copic hematuria, higher histological grade, lower
FR, and greater proteinuria. However, consider-
ng multiple risk factors simultaneously, only male
ex, baseline GFR, proteinuria level, and high his-
opathologic score proved to be significant and
ndependent predictors of disease progression.
hese findings are consistent with data from
ost published studies, in which poor renal func-
ion and heavy proteinuria at the time of biopsy
r initiation of the disease and severity of histo-
ogical lesions emerged as independent predic-
ors of poor outcome.5-12 In the present study,
bsence of episodes of gross hematuria and male
ex showed only a borderline effect on progno-
is, a finding concordant with previous studies in
hich, with few exceptions, these risk factors
ost their prognostic value when evaluated by
sing multivariate analysis.5
The role of treatment with steroids and ACE
nhibitors/ARBs on survival rate was not ana-
yzed in previous studies of familial versus spo-
adic IgA nephropathy. In the present large co-
ort of adult patients with IgA nephropathy,
ultivariate analysis showed for the first time an
ndependent protective effect of ACE-inhibitor/
RB and steroid therapy. Although not statisti-
ally significant, a trend toward an additional
Table 2. Stratified Cox Proportional Haza
Variable B
poradic v familial 0.042
ex (male v female) 0.527
ypertension (yes v no) 0.365
acrohematuria v microhematuria 0.321
istological grade (G2 v G1) 0.512
istological grade (G3 v G1) 1.059
FR (30-60 v60 mL/min) 0.788
FR (30 v60 mL/min) 1.667
rinary protein (1-3 v1 g/d) 0.855
rinary protein (3 v1 g/d) 1.550
CE inhibitor only (v neither) 0.722
teroid only (v neither) 1.131
teroid ACE inhibitor (v neither) 0.257
NOTE. N 177 events. Hazard ratios and 95% CIs of ha
odel are listed. Center effect (Brescia and Bari) and age (
Es are adjusted for clustering on family code. The model
here was no violation of the proportional hazards assumpurvival advantage compared with either treat- qent alone was observed in patients treated with
oth ACE inhibitors/ARBs and steroids. The
bservational design of our study precludes the
stablishment of causality. However, these re-
ults confirm the beneficial influence of ACE
nhibitors and steroids on the course of IgA
ephropathy, already described in different and
ppropriate studies.26-28
More recently, a new factor was reported that
ight have an independent effect contributing to
he progression of IgA nephropathy: the presence
f familial disease. Familial IgA nephropathy
eems to have a much worse prognosis than the
poradic form.20
Comparison of the renal phenotype of patients
ith the familial and sporadic forms of IgA
ephropathy, with particular emphasis on risk for
rogression, was the major aim of our study.
hus, the present study is designed to detect, if
resent, a clinically relevant difference in renal
utcome between the 2 types of disease (familial/
poradic relative risk for progression to ESRD
0.6 or 1.7), with a power of 90% and a
robability of rejecting the null hypothesis when
t is true ( error) of 0.05. Although there still
emains a risk of 10% of failing to reject the null
ypothesis of effect equality when it is actually
alse ( error), to our knowledge, this study pro-
ides the most powerful answer to the prognostic
cedure of Time to Halving GFR or ESRD
P Hazard Ratio
95% CI for
Hazard Ratio
0.858 0.95 0.60-1.52
0.005 1.69 1.16-2.45
0.086 1.44 0.94-2.18
0.081 0.72 0.50-1.04
0.084 1.67 0.93-2.98
0.002 2.88 1.49-5.56
0.001 2.19 1.36-3.55
<0.001 5.29 3.07-9.13
<0.001 2.35 1.51-3.64
<0.001 4.71 2.90-7.64
<0.001 0.48 0.32-0.72
0.031 0.31 0.11-0.89
0.436 0.77 0.40-1.47
tios for progression associated with covariates in the final
) are accounted for by stratification, discussed in Methods.
y significant (Wald chi-square[13]  272.18; P  0.0001).
sults that have P0.05 are indicated in bold.rds Pro
SE
0.236
0.189
0.213
0.184
0.296
0.335
0.245
0.278
0.223
0.246
0.202
0.528
0.330
zard ra
tertiles
is highluestions related to type of IgA nephropathy.
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FAMILIAL AND SPORADIC IGA NEPHROPATHY 767To date, only 2 studies examined in detail the
enal phenotype of patients with sporadic and
amilial IgA nephropathy, giving controversial
esults. In the first study, Julian et al19 compared
1 patients with familial IgA nephropathy and 17
atients with the sporadic form of disease. Ac-
ording to Julian et al,19 clinical findings, such as
ean age at apparent clinical onset of disease,
ge at time of renal biopsy, degree of micro-
copic hematuria, history of macroscopic hema-
uria, magnitude of daily proteinuria, and renal
rognosis, were similar in patients with familial
nd sporadic disease. In addition, histological
ndings and frequency of the immunoglobulin
sotype and C3 in renal biopsy specimens did not
iffer.
More recently, Schena et al20 reported that
atients with familial IgA nephropathy appeared
o have a more aggressive form of disease. Renal
henotype was compared in 39 patients with
amilial and 25 patients with sporadic IgA ne-
hropathy. Predominance of male sex, mean age
t time of renal biopsy, and history of macro-
copic hematuria were similar in those with
amilial and sporadic IgA nephropathy. More-
ver, at the time of renal biopsy, no difference
as found in laboratory findings, including se-
um IgA level, creatinine clearance, and protein-
ria, between the 2 groups, as well as severity of
istological lesions. However, despite this clini-
al and histological similarity, renal survival was
ignificantly worse in patients with familial IgA
ephropathy. According to that study, familial
gA nephropathy may be considered a nonbenign
isease, characterized by a poorer outcome than
he sporadic form of IgA nephropathy.
These studies may just have inadequate sample
ize to draw firm conclusions. For this reason,
arger epidemiological studies appear necessary
o test the hypothesized association between form
f IgA nephropathy and renal outcome.
In our study population, at the time of renal
iopsy, the group of patients with sporadic dis-
ase was composed of more severely ill symptom-
tic subjects, suggested by greater serum creati-
ine levels, more severe histological lesions and
roteinuria, and increased frequency of arterial
ypertension. This probably reflects different
imes of diagnosis, rather than different severity
f the 2 forms. In other words, our clinical
ractice to obtain an accurate family history and derform urinalysis in all family members of
atients with IgA nephropathy may favor earlier
etection of the disease in the subset of patients
ith familial IgA nephropathy with asymptom-
tic and possibly less severe illness. Stronger
linical suspicion, leading to earlier diagnosis,
ay lead to a phenomenon known as lead-time
ias in survival studies. In an ideal prognostic
tudy, an inception cohort should be assembled
ith a common time zero for time-to-event anal-
sis. Practically, this time zero is when the diag-
osis is made, but this can vary in relation to the
rue disease course. Lead-time bias occurs if
here is a systematic difference between groups
n the timing of diagnosis in relation to disease
ourse. Lead-time bias confers an apparent sur-
ival advantage to individuals diagnosed in the
reclinical phase of the disease, and it may be
ery difficult to introduce corrections of this
easurement bias once detection by screening
as occurred more often in 1 of the exposure
roups. One way to correct the effect of lead-
ime bias in prognostic studies in nephrology is
o subtract time segments from those who were
creened and enrolled earlier in the course of
heir disease (or prolong time of those not
creened) by using renal function at baseline and
ate of renal function deterioration. However,
his can be done only under the assumption that
enal function declines linearly and indepen-
ently of any intervention undertaken after diag-
osis to decrease progression and irrespective of
ther factors known to impact on progression,
uch as hypertension or proteinuria. These as-
umptions clearly are untenable, and the validity
f this correction is very uncertain. Furthermore,
he time of biopsy-proven diagnosis remains the
east vague starting point to measure time-to-
vent occurrence in this kind of disease, and
rognostically important markers of renal dis-
ase severity, such as renal function, proteinuria,
nd histological score, can be incorporated use-
ully into a regression model to provide a less
iased estimate of the association of interest.
For all these reasons, although univariate anal-
sis suggested that the sporadic form of IgA
ephropathy was associated significantly with
ncreased risk for renal death, this detrimental
ffect on renal survival disappeared in multiple
ox regression. This suggests that the sporadic
isease was not an independent predictor of renal
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IZZI ET AL768urvival and confirms the role of known con-
ounders.
Our study has limitations. It is an observa-
ional investigation; thus, any exposure-disease
elationship must be interpreted cautiously as
ssociation and not causality. Despite successful
andling of confounding issues, the possibility
f design limitation and residual confounding
annot be ignored. The likelihood of selection
ias seems low because of the meticulous record
earch in different registries and centers and
fficient variable definitions. However, we ac-
nowledge that these same risk factors for renal
ortality, such as hypertension and proteinuria,
ere assessed only at the study start and not
uring follow-up, precluding analysis of the im-
act of their change over time. Finally, our anal-
sis is limited with respect to exploring other
otential recently identified predictors of the
evelopment of ESRD, such as obesity, smok-
ng, and inflammation markers.29-31
In summary, results of the present study sug-
est that one cannot differentiate between famil-
al and nonfamilial IgA nephropathy with respect
o clinical features of disease. In particular, we
re unable to confirm previous suggestions that
atients with familial IgA nephropathy have a
uch worse prognosis than those with sporadic
orms of IgA nephropathy because a similar
linical long-term outcome between the 2 groups
f patients was observed. Thus, today, familial
isease cannot be added to the growing list of
ndependent factors contributing to the overall
rognosis of patients with IgA nephropathy.
To conclude, we can speculate that the similar-
ty of renal phenotype may represent a compel-
ing argument in favor of a common pathogenic
echanism underlying familial and sporadic IgA
ephropathy. This offers the possibility that iden-
ification of the gene(s) for familial IgA nephrop-
thy might shed light on the pathogenesis of the
poradic form of the disease.
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